Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | MEN1 | O00255 | 8/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 11/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 2/20 | 0.58 |
| ▸ | METAP2 | P50579 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317836 | 0.87 | KMT2A (1.00) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL6609076 | 0.87 | ALDH1A1 (0.77) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL8724077 | 0.80 | MAPT (0.67) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL11973580 | 0.80 | MEN1 (0.77) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL29777337 | 0.80 | MAPT (0.67) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL8751507 | 0.80 | MAPT (0.67) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL5188552 | 0.80 | MAPT (0.67) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL1552872 | 0.80 | MAPT (1.00) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL17597346 | 0.78 | KMT2A (0.70) | ALDH1A1KMT2AMEN1KDM4ETDP1 | |
| SCHEMBL2111476 | 0.78 | MAPT (1.00) | ALDH1A1KMT2AMEN1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091127-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2025-05-08 | — | — | WO | disclosed |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016040764-A1 | CARBONYL LINKED BICYCLIC HETEROARYL N-BENZIMIDAZOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | KANE JOHN L JR | 2007-11-01 | — | — | US | disclosed |
| US-4933447-A | FOR TREATMENT OF CARDIOVASCULAR DISORDERS | SS PHARMACEUTICAL CO., LTD. (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0308897-A1 | Quinoline derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1989-03-29 | — | — | EP | disclosed |
| US-4801717-A | PLANT GROWTH REGULATORS | ROUSSEL UCLAF (FR) | 1989-01-31 | — | — | US | disclosed |
| EP-0119892-B1 | HYDROXYL AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS GROWTH FACTORS FOR VEGETABLES AND COMPOSITIONS THEREOF | ROUSSEL-UCLAF (FR) | 1986-08-13 | — | — | EP | disclosed |
| EP-0119892-A1 | Hydroxyl amine derivatives, their preparation, their use as growth factors for vegetables and compositions thereof | ROUSSEL-UCLAF (FR) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | ALDH1A1 1470/4885KMT2A 1323/4885MEN1 2604/4885 |
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | MKI67, VEGFA, KDR | ALDH1A1 1480/4885KMT2A 4653/4885MEN1 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.